The bone morphogenetic protein market is expected to grow over the next eight years, according to a Grand View Research report.
Here are five key trends:
1. The BMP market is expected to reach $644.6 million in 2024. The increase of spinal fusions, trauma and small bone surgeries will drive the increase over time.
2. In 2015, rhBMP-2 had more than half the market share for BMPs due to a higher acceptance rate among surgeons, wide application range and ease of availability in developing countries.
3. The use of rhBMP-7 is expected to drop in market share over the next few years, especially after Olympus discontinued OP-1 in 2014.
4. Spinal fusion reported the largest market share of BMP use in 2015.
5. North America accounted for 65 percent of the BMP market in 2015 with a high number of orthopedic surgeries available and favorable reimbursement policies in the country.